Abbott Raises Profit Forecast Amid Strong Performance from Diagnostics and Medical Devices
Abbott Laboratories (NYSE:ABT) reported strong fiscal Q2 2026 results with a significant increase in quarterly sales, driven by robust demand for its cancer diagnostics and medical devices. The company raised its full-year adjusted diluted EPS guidance to $5.45–$5.60 from the previous range of $5.38–$5.58, reflecting confidence in sustained growth. The standout performer was Abbott's diagnostics segment, which saw a 42% year-over-year sales increase due to strong adoption and repeat use of its Cologuard colorectal cancer screening test following the Exact Sciences acquisition. Analysts from William Blair reiterated an Outperform rating on ABT shares after the results helped alleviate concerns about hospital procedure volumes. Looking ahead, Abbott's growth in H2 2026 will depend heavily on successful commercialization of key pipeline products such as Amulet 360 and Volt. While sales across all segments are expected to improve, nutrition business performance remains a concern due to declining reported and comparable sales.
Tickers: $ABT
Topics: cancer_screening diagnostics eps_guidance medical_devices